Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Bristol-Myers Squibb Company v. Teva Pharmaceuticals USA, Inc
Case Number:
13-1306
Court:
Nature of Suit:
830 Patent Infringement (Fed. Question)
Companies
Sectors & Industries:
-
October 20, 2014
Full Fed. Circ. Won't Review BMS Hepatitis Drug Patent Ruling
The full Federal Circuit refused Monday to review a decision invalidating a Bristol-Myers Squibb Co. hepatitis B drug patent as obvious, even though the compound it was based on was later found to be toxic, but several judges argued strongly that the ruling makes it too hard to show a patent is not obvious.
-
August 26, 2014
Fed. Circ. Told To Nix En Banc Bid In Bristol-Myers IP Case
Teva Pharmaceuticals USA Inc. on Tuesday urged the Federal Circuit to reject Bristol-Myers Squibb Co.'s bid for en banc rehearing of a decision invalidating the patent on its hepatitis B drug Baraclude as obvious, saying that Bristol-Myers' position "flies in the face" of settled law on obviousness.
-
July 15, 2014
Bristol-Myers Wants Fed. Circ.'s En Banc Review Of Patent
Bristol-Myers Squibb Co. on Monday pressed the Federal Circuit for another chance to show its patent for hepatitis B drug Baraclude was valid, arguing that the court's decision affirming the patent invalid as obvious in a Teva Pharmaceuticals USA Inc. dispute conflicted with U.S. Supreme Court precedent.
-
June 12, 2014
Fed. Circ. Upholds Ruling Nixing BMS Hepatitis Drug Patent
The Federal Circuit on Wednesday affirmed a lower court's decision that a Bristol-Myers Squibb Co. patent covering the hepatitis B drug Baraclude is invalid as obvious because it made only minor changes to the prior art, in a win for generics maker Teva Pharmaceuticals USA Inc.
-
December 05, 2013
BMS Urges Fed. Circ. To Revive Hepatitis B Drug Patent
Bristol-Myers Squibb pushed a Federal Circuit panel on Thursday to revive its patent covering the hepatitis B drug Baraclude, alleging a lower court applied improper legal standards when it found in favor of generic-drug maker Teva Pharmaceutical Industries Ltd. and determined that Bristol-Myers' patent was obvious.
-
August 27, 2013
Hepatitis B Patent Ruling 'Infected,' BMS Tells Fed. Circ.
Bristol-Myers Squibb Co. on Monday urged the Federal Circuit to reverse a decision that invalidated its patent covering the hepatitis B drug Baraclude, arguing that the district court relied on faulty legal reasoning to determine that the drug was obvious in favor of generic-drug maker Teva Pharmaceutical Industries Ltd.